Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 180 participants.
Also called NCT07827521
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 180 participants
- Registry
-
NCT07827521
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07827521. Randomized; single masking; primary purpose treatment. Start 2026-10-20 (anticipated); primary completion 2028-10-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia
- Condition
- Chronic Limb-Threatening Ischemia
- Condition
- Diabetic Foot Ulcer
- Condition
- Infrapopliteal Arterial Occlusive Disease
- Intervention (Procedure)
- Lower-Extremity Revascularization
- Intervention (Genetic)
- Donaperminogene Seltoplasmid
- Lead sponsor
- First Affiliated Hospital of Wenzhou Medical University
- Collaborator
- Beijing Northland Biotech. Co., Ltd.
Record details
- Record id
cardio:ct-nct07827521- Content hash
ca2af17859f925ba5620c1a94c18f837e6ba2169bc630ac591537b5bfefa86a8